Droxidopa Combinations Extend Half-Life for Orthostatic Hypotension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for orthostatic hypotension are unpredictable and often associated with undesirable side effects, necessitating the development of compositions that can effectively manage this condition without type-specific limitations.
Innovation Solution
Combining droxidopa with pharmaceutically active compounds such as entacapone, catechol-O-methyltransferase inhibitors, cholinesterase inhibitors like pyridostigmine, and monoamine oxidase inhibitors to increase the half-life and volume of distribution of droxidopa, thereby enhancing its efficacy in treating orthostatic hypotension.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If droxidopa is administered alone, then it can replenish norepinephrine levels, but its half-life is short requiring frequent dosing
Solution Approach 1:
The patent introduces COMT inhibitors (entacapone, tolcapone) and MAO inhibitors (selegiline, rasagiline) as intermediary substances that block the metabolic degradation of droxidopa. These inhibitors act as mediators between droxidopa and its metabolic breakdown, preventing catechol-O-methyltransferase and monoamine oxidase from rapidly degrading the drug, thereby extending its half-life from approximately 2 hours to 4-6 hours or longer.
2Reliability
If droxidopa is administered alone, then it can treat orthostatic hypotension, but treatment efficacy is limited by rapid metabolism
Solution Approach 1:
The patent converts the harmful rapid metabolism of droxidopa into a benefit by using enzymatic inhibition. The COMT and MAO inhibitors, which normally function to degrade catecholamines, are repurposed to specifically protect droxidopa from degradation. This transforms the body's natural drug-metabolizing enzymes from harmful agents into controlled protective mechanisms, extending drug availability and improving orthostatic hypotension treatment efficacy.
3Reliability
If current treatments for orthostatic hypotension are used, then blood pressure can be managed, but side effects are frequent and unpredictable
Solution Approach 1:
The patent changes the pharmacokinetic parameters of droxidopa by combining it with metabolic inhibitors. This parameter change extends the half-life and area under the curve (AUC) of droxidopa, allowing for more stable and predictable plasma concentrations. The result is more reliable blood pressure management with reduced side effects, as the drug maintains therapeutic levels without the peaks and troughs associated with frequent dosing of droxidopa alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of droxidopa with these compounds significantly increases the half-life and volume of distribution of droxidopa, allowing for reduced dosing frequencies and improved treatment efficacy for orthostatic hypotension, while minimizing side effects.
Implementation Method 1
it is directly converted to 1-norepinephrine by the action of the aromatic L-amino acid decarboxylase which is widely distributed in a living body
Implementation Method 2
Combining droxidopa with pharmaceutically active compounds such as entacapone, catechol-O-methyltransferase inhibitors, cholinesterase inhibitors like pyridostigmine, and monoamine oxidase inhibitors to increase the half-life and volume of distribution of droxidopa
Data Source
Figure 1
AI summary
The present invention provides combinations of droxidopa and one or more further pharmaceutically active compounds, said further compounds preferentially being selected from the group of COMT inhibiting compounds, cholinesterase inhibiting compounds, and monoamine oxidase inhibiting compounds. The invention further provides methods of treating conditions, such as orthostatic hypotension, comprising administering the combinations.